Orion Oyj

Orion Oyj, a pharmaceutical enterprise founded in 1917 and based in Espoo, Finland, operates globally in the development, manufacturing, and commercialization of medicines for both human and animal health, in addition to active pharmaceutical ingredients (APIs). Its market presence encompasses Finland, Scandinavia, other European countries, North America, and various international territories. The company's human pharmaceutical portfolio includes a diverse array of prescription and self-care products. Notable prescription treatments feature Nubeqa for prostate cancer; dexdor and Precedex for intensive care sedation; Stalevo and Comtess/Comtan addressing Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer. Orion also provides its well-known Easyhaler® range, offering multiple formulations like Salmeterol/fluticasone and Budesonide/formoterol, specifically designed for the management of asthma and chronic obstructive pulmonary disease. Within the veterinary segment, Orion produces a selection of animal drugs, including Bonqat, Clevor, and Sileo, and furthermore markets veterinary medicines supplied by other international corporations. Beyond finished products, the company is involved in manufacturing APIs for both generic and proprietary medications, and it extends contract manufacturing services. Orion serves a wide spectrum of clients, including healthcare professionals such as specialists, general practitioners, veterinarians, pharmacists, and institutions like hospitals, clinics, and laboratories, alongside pet-owning consumers. The company engages in strategic collaborations, notably a partnership with Propeller Health to integrate connected technology with its Easyhaler® devices for asthma and COPD, and a research and licensing agreement with Alligator Bioscience AB (publ) to advance the discovery of new bispecific antibody cancer therapeutics.